PROTAC ER Degrader-3 is primarily used in research settings to study targeted protein degradation, particularly focusing on estrogen receptor (ER) pathways. It is employed to investigate the degradation of ER proteins in cancer cells, offering insights into potential therapeutic strategies for ER-positive cancers, such as breast cancer. By selectively degrading ER proteins, it helps researchers understand the role of ER signaling in tumor growth and resistance to conventional therapies. This compound is also utilized in the development of novel cancer treatments, aiming to overcome limitations of traditional hormone therapies and improve patient outcomes. Its application extends to studying protein degradation mechanisms and evaluating the efficacy of PROTAC technology in drug discovery.